Goel A, et al. - In real-life- setting, researchers assessed the impact of daclatasvir and half-daily dose of sofosbuvir treatment regimen in chronic kidney disease (CKD) patients with estimated glomerular filtration rate (eGFR) <30 mL/min. Findings demonstrated efficacy of this treatment regiment against genotype 1 and 3 HCV infection in this population. Additionally, this combination could be a pangenotypic treatment option for such patients.